Peer review reports
From: Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
Original Submission | ||
---|---|---|
13 May 2019 | Submitted | Original manuscript |
30 Oct 2019 | Reviewed | Reviewer Report - Joseph C. del Paggio |
23 Mar 2020 | Reviewed | Reviewer Report |
4 May 2020 | Author responded | Author comments - Fei Liang |
Resubmission - Version 2 | ||
4 May 2020 | Submitted | Manuscript version 2 |
12 May 2020 | Reviewed | Reviewer Report |
12 Jul 2020 | Reviewed | Reviewer Report |
7 Aug 2020 | Author responded | Author comments - Fei Liang |
Resubmission - Version 3 | ||
7 Aug 2020 | Submitted | Manuscript version 3 |
14 Aug 2020 | Author responded | Author comments - Fei Liang |
Resubmission - Version 4 | ||
14 Aug 2020 | Submitted | Manuscript version 4 |
Publishing | ||
18 Aug 2020 | Editorially accepted | |
31 Aug 2020 | Article published | 10.1186/s12885-020-07313-2 |